Table 1.
MIST1 expression in human plasma cell neoplasms
| Sex | Age, yr | Tissue | Final Diagnosis | CD138+ Plasma Cells, % | Mist+ Plasma Cells, % |
|---|---|---|---|---|---|
| F | 44 | Left humerus | Extramedullary plasma cell myeloma | >90 | >90 |
| F | 61 | Right neck | Plasmacytoma | >90 | 50–75 |
| F | 74 | T3 vertebrae | Plasmacytoma | 25–50 | 25–50 |
| F | 80 | Sacrum | Extramedullary plasma cell myeloma | >90 | >90 |
| M | 59 | Right distal tibia | Extramedullary plasma cell myeloma | >90 | >90 |
| M | 67 | T1 vertebrae | Extramedullary plasma cell myeloma | 50–75 | >90 |
| F | 62 | Right axillary lymph node | Plasmacytoma | 25–50 | 25–50 |
| F | 63 | Left pubic ramus | Plasmacytoma with anaplastic features | >90 | >90 |
| M | 69 | Liver | Extramedullary plasma cell myeloma | >90 | >90 |
| M | 72 | T6 vertebrae | Extramedullary plasma cell myeloma | >90 | >90 |
| F | 48 | Bone marrow (∼10% plasma cells) | Plasma cell myeloma | >90 | >90 |
| M | 68 | Bone marrow (∼10% plasma cells) | Plasma cell myeloma | >90 | >90 |
Fraction of cells with plasma cell differentiation that were positive for CD138 and MIST1 expression was scored from biopsies of patients with various plasma cell lesions and diagnoses.